Skip to main content
Premium Trial:

Request an Annual Quote

DNAVision to Offer Ipsogen's MapQuant Breast Cancer Test

NEW YORK (GenomeWeb News) – DNAVision said yesterday that it will offer Ipsogen’s new MapQuant Dx Genomic Grade test through its central lab services in Europe.
 
The MapQuant Dx is a molecular diagnostic, gene expression-based test that measures tumor grade, risk of metastasis, and chemotherapy response, among breast cancer patients. Ipsogen launched the test last week.
 
The MapQuant runs on Affymetrix’s GeneChip platform and was developed under an agreement between Affy and Marseille, France-based Ipsogen in August 2007.
 

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.